Benefits for pre-approval of six new PNH patients for Ultomiris administration were approved and four cases were rejected. There were no applications for new salary administration for Soliris, but two applications for pre-approval for new aHUS patients were not accepted.

In the case of Spinraza, a treatment for Spinal Muscular Atrophy (SMA), one application for new patient benefits and two data supplementations were decided. Of the 25 monitoring reports, 23 were approved and 2 were disapproved.

The HIRA conducted deliberation on six items, including Soliris and Ultomiris, and whether hospitalization fees were recognized. According to the results of the deliberation on the 2nd, Soliris decided